Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Pharmaceutical companies

Pfizer and Allergan announce US$160bn merger deal

Pfizer is merging with Dublin-based Allergan in a US$160bn deal that will create the biggest pharmaceutical company in the world. In the image, Ian Read, chief executive officer of Pfizer

Source: Rex Shutterstock

Pfizer’s chairman and chief executive officer Ian Read says the merger will create a ‘leading global pharmaceutical company’

Pfizer is merging with Dublin-based Allergan in a US$160bn deal that will create the biggest pharmaceutical company in the world, the companies announced on 23 November 2015.

Pfizer will keep its global headquarters in the United States but will transfer its principal executive team to Ireland — a decision that some business analysts saw as a move by the company to lower its tax liabilities.

The new company will be called Pfizer plc and the deal, which still needs regulatory approval in the European Union as well as the United States, is expected to be completed by the second half of 2016.

“The proposed combination of Pfizer and Allergan will create a leading global pharmaceutical company with the strength to research, discover and deliver more medicines and therapies to more people around the world,” says Pfizer’s chairman and chief executive officer Ian Read.

Brent Saunders, chief executive officer at Allergan, says the merger will allow Allergan to “operate with greater resources at a much bigger scale”.

“Joining forces with Pfizer matches our leading products in seven high-growth therapeutic areas and our robust research and development pipeline with Pfizer’s leading innovative and established businesses, vast global footprint and strength in discovery and development research to create a new biopharma leader,” adds Saunders.

The merger boosts Pfizer’s share of the market in areas including women’s health, anti-infectives, aesthetics, dermatology, eye care, gastrointestinal, neuroscience and urology. The new company will have a combined pipeline of more than 100 mid-to-late stage programmes in development. Allergan also brings its topical formulation, manufacturing and its Anda distribution business to the new company.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200153

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Pfizer is merging with Dublin-based Allergan in a US$160bn deal that will create the biggest pharmaceutical company in the world. In the image, Ian Read, chief executive officer of Pfizer

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.